{"created":"2023-05-15T14:47:14.731533+00:00","id":64788,"links":{},"metadata":{"_buckets":{"deposit":"d9245caf-1edd-4e1a-bd3e-4485d921a7ce"},"_deposit":{"created_by":1,"id":"64788","owners":[1],"pid":{"revision_id":0,"type":"depid","value":"64788"},"status":"published"},"_oai":{"id":"oai:repo.qst.go.jp:00064788","sets":["10:29"]},"author_link":["638318","638313","638321","638315","638317","638322","638320","638314","638316","638319"],"item_10005_date_7":{"attribute_name":"発表年月日","attribute_value_mlt":[{"subitem_date_issued_datetime":"2012-10-13","subitem_date_issued_type":"Issued"}]},"item_10005_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"抗精神病薬の大多数は脳内ドーパミンD2レセプターの遮断薬であるが、本研究では部分作動薬である抗精神病薬のアリピプラゾールがドーパミン作動性神経の前シナプス機能に及ぼす影響について検討した。男性健常者12名を対象に、アリピプラゾール3〜9 mgの服薬前と服薬後のそれぞれで、[C-11]DOPAおよび[C-11]racloprideを用いたPET検査を行い、線条体における服薬による脳内ドーパミン生成能の変化およびドーパミンD2レセプター占有率を測定した。服薬によるドーパミン生成能変化率とドーパミンD2レセプター占有率との間に明らかな相関はみとめられなかったが、服薬前のドーパミン生成能と服薬によるドーパミン生成能変化率との間には有意な負の相関がみられ(r=0.65, P＜0.05)、ドーパミン生成能が服薬により一定値に収束する傾向がみられた。これはアリピプラゾールにドーパミン生成能を安定化させる作用があることを示唆するものであり、統合失調症における治療効果発現に関与している可能性がある。","subitem_description_type":"Abstract"}]},"item_10005_description_6":{"attribute_name":"会議概要（会議名, 開催地, 会期, 主催者等）","attribute_value_mlt":[{"subitem_description":"第52回日本核医学会学術総会","subitem_description_type":"Other"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"metadata only access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_14cb"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"伊藤, 浩"}],"nameIdentifiers":[{"nameIdentifier":"638313","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"高野, 晴成"}],"nameIdentifiers":[{"nameIdentifier":"638314","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"高畑, 圭輔"}],"nameIdentifiers":[{"nameIdentifier":"638315","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"小高, 文聰"}],"nameIdentifiers":[{"nameIdentifier":"638316","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"須原, 哲也"}],"nameIdentifiers":[{"nameIdentifier":"638317","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"伊藤 浩","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"638318","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"高野 晴成","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"638319","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"高畑 圭輔","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"638320","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"小高 文聰","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"638321","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"須原 哲也","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"638322","nameIdentifierScheme":"WEKO"}]}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"conference object","resourceuri":"http://purl.org/coar/resource_type/c_c94f"}]},"item_title":"抗精神病薬アリピプラゾールによる脳内ドーパミン生成能の変化","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"抗精神病薬アリピプラゾールによる脳内ドーパミン生成能の変化"}]},"item_type_id":"10005","owner":"1","path":["29"],"pubdate":{"attribute_name":"公開日","attribute_value":"2012-10-15"},"publish_date":"2012-10-15","publish_status":"0","recid":"64788","relation_version_is_last":true,"title":["抗精神病薬アリピプラゾールによる脳内ドーパミン生成能の変化"],"weko_creator_id":"1","weko_shared_id":-1},"updated":"2023-05-15T21:07:37.679817+00:00"}